Galapagos Nv Adr (GLPG)

Jan 21, 2025

Galapagos To Spin Off Innovative Medicines Business - Forbes

Jan 21, 2025

Jan 08, 2025

Galapagos Unveils 2025 Split To Accelerate Innovation, Sharpen Strategic Focus - Benzinga

Jan 08, 2025

Nov 20, 2024

Galapagos stock downgraded to Reduce on strategic concerns - Investing.com

Nov 20, 2024

Nov 20, 2024

Galapagos stock downgraded to Reduce on strategic concerns By Investing.com - Investing.com South Africa

Nov 20, 2024

Nov 14, 2024

Belgium shares higher at close of trade; BEL 20 up 0.58% - MSN

Nov 14, 2024

Nov 04, 2024

Deutsche Bank maintains Hold on Galapagos, reducing target with key updates months away - Investing.com

Nov 04, 2024

Nov 01, 2024

Earnings call: Galapagos reports solid Q3 progress, eyes IND studies By Investing.com - Investing.com South Africa

Nov 01, 2024

Nov 01, 2024

Earnings call: Galapagos reports solid Q3 progress, eyes IND studies - Investing.com

Nov 01, 2024

Nov 01, 2024

Galapagos stock outlook cautious with clinical readouts on the horizon, says Morgan Stanley - Investing.com

Nov 01, 2024

Oct 30, 2024

Galapagos ADR earnings missed by $0.05, revenue topped estimates - Investing.com UK

Oct 30, 2024

Sep 09, 2024

Leerink Partners gives Market Perform rating to Galapagos NV stock, flags R&D challenges - Investing.com

Sep 09, 2024

Aug 27, 2024

Navigating GLPG Stock: Galapagos NV ADR Journey - The InvestChronicle

Aug 27, 2024

Aug 26, 2024

Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket - Benzinga

Aug 26, 2024

Aug 23, 2024

Galapagos (GLPG) Up on FDA Nod to Begin Phase I/II Lymphoma Study - Yahoo Finance

Aug 23, 2024

Aug 03, 2024

Morgan Stanley cuts Galapagos NV target to $32 from $35 - Investing.com

Aug 03, 2024

Aug 02, 2024

Earnings call: Galapagos focuses on oncology and immunology in H1 2024 report - Investing.com

Aug 02, 2024

Jul 15, 2024

Belgium stocks lower at close of trade; BEL 20 down 0.90% - Investing.com

Jul 15, 2024

May 30, 2024

Adaptimmune and Galapagos partner on cancer therapy - Investing.com

May 30, 2024

Apr 17, 2024

Citi lowers Galapagos NV shares target amid restructuring and pipeline investments By Investing.com - Investing.com

Apr 17, 2024

Mar 07, 2024

Morgan Stanley sets Galapagos stock at equalweight, $38 price target - Investing.com

Mar 07, 2024

May 30, 2022

Morgan Stanley lists biotechs with negative enterprise value, 2022 catalysts (NASDAQ:GLPG) - Seeking Alpha

May 30, 2022

Dec 30, 2020

Galapagos: Market Values Pipeline Below $0 (NASDAQ:GLPG) - Seeking Alpha

Dec 30, 2020

Aug 19, 2020

The Daily Biotech Pulse: Gilead's Filgotinib Stumbles With FDA, J&J Laps Up Momenta In $6.5B Deal, 2 IPOs - Benzinga

Aug 19, 2020

Aug 16, 2020

The Week Ahead In Biotech: Spotlight On Gilead, BioMarin FDA Decisions, IPOs - Yahoo Finance

Aug 16, 2020

Jan 17, 2020

The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares - Yahoo Finance

Jan 17, 2020

Apr 30, 2019

World’s Top-Selling Drugs: Gilead Sciences, Inc. Sovaldi Closes In On AbbVie Inc Humira - Crypto Coins Tribune

Apr 30, 2019

Apr 17, 2019

Galapagos NV (GLPG) Stock Price, Trades & News - GuruFocus.com

Apr 17, 2019

Jul 27, 2018

AIM tech shares that broke America - Interactive Investor

Jul 27, 2018

Jul 07, 2017

Galapagos Is More Attractive–But Don’t Buy It Just Yet - Barron's

Jul 07, 2017

Dec 30, 2015

The 5 Best-Performing Non-S&P Stocks of 2015 - Forbes

Dec 30, 2015

Jul 31, 2015

GalapagosAll Time High - Seeking Alpha

Jul 31, 2015

May 24, 2015

Galapagos NV ADR (NQ: GLPG - Financial Content

May 24, 2015